-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Bought by Barclays PLC
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Bought by Barclays PLC
Barclays PLC raised its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating) by 1,792.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 189,290 shares of the biotechnology company's stock after acquiring an additional 179,290 shares during the period. Barclays PLC owned 0.24% of Anavex Life Sciences worth $1,953,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently bought and sold shares of AVXL. Lazard Asset Management LLC acquired a new position in Anavex Life Sciences in the second quarter valued at $26,000. SeaCrest Wealth Management LLC acquired a new position in Anavex Life Sciences in the second quarter valued at $44,000. Quantbot Technologies LP acquired a new position in Anavex Life Sciences in the second quarter valued at $64,000. Janney Montgomery Scott LLC acquired a new position in Anavex Life Sciences in the third quarter valued at $108,000. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of Anavex Life Sciences during the first quarter worth about $136,000. Institutional investors and hedge funds own 31.22% of the company's stock.
Get Anavex Life Sciences alerts:Anavex Life Sciences Stock Down 1.0 %
Shares of NASDAQ:AVXL opened at $11.26 on Friday. The company has a market cap of $878.62 million, a P/E ratio of -18.16 and a beta of 0.77. Anavex Life Sciences Corp. has a 52 week low of $7.13 and a 52 week high of $15.24. The company has a 50-day moving average price of $9.60 and a 200 day moving average price of $10.46.
Anavex Life Sciences (NASDAQ:AVXL – Get Rating) last announced its quarterly earnings data on Monday, November 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.02). Analysts expect that Anavex Life Sciences Corp. will post -0.81 EPS for the current year.Analysts Set New Price Targets
Several brokerages have recently weighed in on AVXL. StockNews.com began coverage on shares of Anavex Life Sciences in a research note on Wednesday, October 12th. They set a "sell" rating for the company. Jonestrading increased their target price on shares of Anavex Life Sciences from $40.00 to $80.00 in a research note on Friday, December 2nd. HC Wainwright increased their target price on shares of Anavex Life Sciences from $42.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday, January 3rd. Finally, Cantor Fitzgerald downgraded shares of Anavex Life Sciences from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $16.00 to $11.00 in a research note on Tuesday, December 6th.
About Anavex Life Sciences
(Get Rating)
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome.
Further Reading
- Get a free copy of the StockNews.com research report on Anavex Life Sciences (AVXL)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating).
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Barclays PLC raised its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating) by 1,792.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 189,290 shares of the biotechnology company's stock after acquiring an additional 179,290 shares during the period. Barclays PLC owned 0.24% of Anavex Life Sciences worth $1,953,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
根据巴克莱集团向美国证券交易委员会(SEC)提交的最新13F表文件,巴克莱集团在第三季度将其在Anavex Life Sciences Corp.(纳斯达克股票代码:AVXL — 获取评级)的股份提高了1,792.9%。该机构投资者在此期间又收购了179,290股生物技术公司的股票后,拥有该生物技术公司的189,290股股票。截至最近向美国证券交易委员会(SEC)提交文件时,巴克莱集团拥有Anavex Life Sciences0.24%的股份,价值19.53万美元。
Several other large investors also recently bought and sold shares of AVXL. Lazard Asset Management LLC acquired a new position in Anavex Life Sciences in the second quarter valued at $26,000. SeaCrest Wealth Management LLC acquired a new position in Anavex Life Sciences in the second quarter valued at $44,000. Quantbot Technologies LP acquired a new position in Anavex Life Sciences in the second quarter valued at $64,000. Janney Montgomery Scott LLC acquired a new position in Anavex Life Sciences in the third quarter valued at $108,000. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of Anavex Life Sciences during the first quarter worth about $136,000. Institutional investors and hedge funds own 31.22% of the company's stock.
其他几位大型投资者最近也买入和卖出了AVXL的股票。拉扎德资产管理有限责任公司在第二季度收购了Anavex Life Sciences的新职位,价值26,000美元。SeaCrest Wealth Management LLC在第二季度收购了Anavex Life Sciences的新职位,价值44,000美元。Quantbot Technologies LP在第二季度收购了Anavex Life Sciences的新职位,价值64,000美元。詹尼·蒙哥马利·斯科特有限责任公司在第三季度收购了Anavex Life Sciences的新职位,价值10.8万美元。最后,Atria Wealth Solutions Inc.在第一季度收购了Anavex Life Sciences股票的新股份,价值约13.6万美元。机构投资者和对冲基金拥有该公司31.22%的股票。
Anavex Life Sciences Stock Down 1.0 %
Anavex 生命科学股价下跌 1.0%
Shares of NASDAQ:AVXL opened at $11.26 on Friday. The company has a market cap of $878.62 million, a P/E ratio of -18.16 and a beta of 0.77. Anavex Life Sciences Corp. has a 52 week low of $7.13 and a 52 week high of $15.24. The company has a 50-day moving average price of $9.60 and a 200 day moving average price of $10.46.
纳斯达克股票代码:AVXL的股价周五开盘价为11.26美元。该公司的市值为8.7862亿美元,市盈率为-18.16,beta为0.77。Anavex Life Sciences Corp. 创下52周低点7.13美元,创下52周高点15.24美元。该公司的50天移动平均价格为9.60美元,200天移动平均线价格为10.46美元。
Analysts Set New Price Targets
分析师设定了新的价格目标
Several brokerages have recently weighed in on AVXL. StockNews.com began coverage on shares of Anavex Life Sciences in a research note on Wednesday, October 12th. They set a "sell" rating for the company. Jonestrading increased their target price on shares of Anavex Life Sciences from $40.00 to $80.00 in a research note on Friday, December 2nd. HC Wainwright increased their target price on shares of Anavex Life Sciences from $42.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday, January 3rd. Finally, Cantor Fitzgerald downgraded shares of Anavex Life Sciences from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $16.00 to $11.00 in a research note on Tuesday, December 6th.
最近有几家经纪公司对AVXL进行了权衡。StockNews.com在10月12日星期三的一份研究报告中开始报道Anavex Life Sciences的股票。他们为公司设定了 “卖出” 评级。Jonestrading在12月2日星期五的一份研究报告中将Anavex Life Sciences股票的目标价格从40.00美元上调至80.00美元。HC Wainwright在1月3日星期二的一份研究报告中将Anavex Life Sciences股票的目标价格从42.00美元上调至50.00美元,并将该股评为 “买入”。最后,坎托·菲茨杰拉德在12月6日星期二的一份研究报告中将Anavex Life Sciences的股票评级从 “增持” 下调至 “中性” 评级,并将该股的目标价格从16.00美元下调至11.00美元。
About Anavex Life Sciences
关于 Anavex 生命科学
(Get Rating)
(获取评分)
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome.
Anavex Life Sciences Corp. 是一家临床阶段的生物制药公司,从事治疗神经退行性和神经发育疾病的不同疗法的开发。其主要化合物 ANAVEX2-73 正在开发中,用于治疗阿尔茨海默氏症和帕金森氏病以及包括雷特综合征在内的中枢神经系统疾病。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Anavex Life Sciences (AVXL)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- 免费获取 StockNews.com 关于 Anavex Life Sciences (AVXL) 的研究报告
- 细价股值得吗?你应该投资细价股吗?
- Zimmer Biomet的收益超过预期,增长可能会被定价
- 人工智能软件制造商 EPAM 拥有最大的科技板块涨势
- 在收益大幅下滑之后,福特股票将向前发展
- 内部人士和机构在全球范围内收购金刚狼
Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating).
想看看还有哪些对冲基金持有 AVXL 吗? 访问Holdingschannel.com,获取Anavex Life Sciences Corp.(纳斯达克股票代码:AVXL — 获取评级)的最新13F文件和内幕交易。
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Anavex 生命科学日报的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Anavex Life Sciences及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧